These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20510168)

  • 21. [The experience of anti-TNF-alpha registries and observatories].
    Sibilia J; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):18-21. PubMed ID: 20510167
    [No Abstract]   [Full Text] [Related]  

  • 22. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles.
    Fife DJ; Waller JM; Jeffes EW; Koo JY
    Dermatol Online J; 2007 May; 13(2):4. PubMed ID: 17498423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
    Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
    Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current topics in psoriasis].
    Boulinguez S
    Ann Dermatol Venereol; 2011 Jun; 138(6 Suppl 1):H1-5. PubMed ID: 21703467
    [No Abstract]   [Full Text] [Related]  

  • 25. New insights and therapies for teenage psoriasis.
    Belazarian L
    Curr Opin Pediatr; 2008 Aug; 20(4):419-24. PubMed ID: 18622197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
    Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
    [No Abstract]   [Full Text] [Related]  

  • 27. Psoriasis and cardiovascular comorbidities with emphasis in Asia.
    Chu TW; Tsai TF
    G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab: new indication. A last resort for treating plaque psoriasis: just another TNF alpha antagonist.
    Prescrire Int; 2008 Dec; 17(98):240. PubMed ID: 19422152
    [No Abstract]   [Full Text] [Related]  

  • 29. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
    Gisondi P; Girolomoni G
    Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.
    Yamauchi PS; Lowe NJ; Gindi V
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S121-2. PubMed ID: 16488323
    [No Abstract]   [Full Text] [Related]  

  • 31. A case of infliximab-induced psoriasis.
    Richetta A; Mattozzi C; Carlomagno V; Maiani E; Carboni V; Giancristoforo S; D'Epiro S; Bruni F; Calvieri S
    Dermatol Online J; 2008 Nov; 14(11):9. PubMed ID: 19094847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research.
    Guttman-Yassky E; Krueger JG
    Br J Dermatol; 2007 Dec; 157(6):1103-15. PubMed ID: 17714560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.
    Bachmeyer C; Thiolière B; Khosrotehrani K; Cattan E
    J Am Acad Dermatol; 2007 Jan; 56(1):169-70. PubMed ID: 17190640
    [No Abstract]   [Full Text] [Related]  

  • 34. What have we learned in dermatology from the biologic therapies?
    Nickoloff BJ; Stevens SR
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S143-51. PubMed ID: 16488330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innate and adaptive immunity and the pathophysiology of psoriasis.
    Gaspari AA
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S67-80. PubMed ID: 16488332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis.
    Jones JL; Berth-Jones J; Fletcher A; Hutchinson PE
    J Pathol; 1994 Oct; 174(2):77-82. PubMed ID: 7525911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis and psoriatic arthritis: separate or one and the same?
    Ciocon DH; Kimball AB
    Br J Dermatol; 2007 Nov; 157(5):850-60. PubMed ID: 17725671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy.
    Desai N; Raste Y; Cooke NT; Harland CC
    Br J Dermatol; 2008 May; 158(5):1137-8. PubMed ID: 18279462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.